Moderna (NASDAQ:MRNA) Stock Price Down 3.4% - Time to Sell?

Moderna, Inc. (NASDAQ:MRNA - Get Free Report) shares were down 3.4% during mid-day trading on Friday. The stock traded as low as $221.70 and last traded at $223.37. 8,023,354 shares were traded during trading, a decline of 36% from the average daily volume of 12,573,938 shares. The stock had previously closed at $231.35.

More Moderna News

Here's some of the latest news about MRNA:

• Positive Sentiment: Moderna raised its 2026 revenue-growth outlook to 15%–25%, up from a previous forecast of up to 10%. The company also highlighted progress in its cancer-vaccine program and broader oncology pipeline, which could provide growth beyond its vaccine business. Article
• Positive Sentiment: Real-world data on mNEXSPIKE in adults 65 and older adds evidence supporting the vaccine’s effectiveness, a potential help for Moderna’s commercial prospects. Article
• Negative Sentiment: The main near-term concern is Moderna’s plan for roughly $4 billion in cash costs in 2027, including investment in oncology. Investors are questioning whether future revenue can justify that spending, and some coverage says the 2026 outlook may still fall short of analyst expectations. Article Article

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on MRNA shares. Wolfe Research upgraded Moderna from an "underperform" rating to a "peer perform" rating in a report on Tuesday, August 25th. CLSA raised shares of Moderna to an "outperform" rating in a research note on Friday, August 28th. Citigroup reiterated a "sell" rating on shares of Moderna in a research report on Friday, October 23rd. Bank of America boosted their price target on shares of Moderna from $170.00 to $200.00 and gave the stock a "neutral" rating in a research note on Friday, October 9th. Finally, Brookline Capital Markets restated a "buy" rating on shares of Moderna in a report on Wednesday, August 19th. Six research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have given a Sell rating to the company's stock. Based on data from MarketBeat.com, Moderna presently has an average rating of "Hold" and an average price target of $113.75.

Moderna Stock Down 3.4%

The firm has a 50 day simple moving average of $200.18 and a two-hundred day simple moving average of $95.52. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.62 and a quick ratio of 3.47. The stock has a market cap of $90.38 billion, a price-to-earnings ratio of -31.46 and a beta of 1.16.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its earnings results on Friday, November 6th. The company reported $0.38 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.10) by $1.48. The firm had revenue of $1.31 billion for the quarter, compared to analysts' expectations of $890.25 million. Moderna had a negative return on equity of 25.79% and a negative net margin of 110.46%. The company's revenue was up 29.2% compared to the same quarter last year. During the same quarter last year, the business earned ($0.51) earnings per share. As a group, sell-side analysts expect that Moderna, Inc. will post -5.34 EPS for the current year.

Insider Buying and Selling

In other Moderna news, President Stephen Hoge sold 40,294 shares of the stock in a transaction on Monday, September 14th. The shares were sold at an average price of $144.13, for a total value of $5,807,574.22. Following the sale, the president directly owned 1,525,858 shares in the company, valued at approximately $219,921,913.54. This trade represents a 2.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of the company's stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total transaction of $485,766.45. Following the completion of the sale, the insider owned 74,129 shares of the company's stock, valued at approximately $10,374,353.55. This represents a 4.47% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 197,251 shares of company stock valued at $33,875,904 in the last 90 days. 10.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Dogwood Wealth Management LLC lifted its holdings in shares of Moderna by 158.8% during the 3rd quarter. Dogwood Wealth Management LLC now owns 132 shares of the company's stock valued at $25,000 after purchasing an additional 81 shares in the last quarter. Western Pacific Wealth Management LP acquired a new stake in Moderna during the 3rd quarter worth approximately $29,000. CENTRAL TRUST Co raised its holdings in shares of Moderna by 36.5% during the third quarter. CENTRAL TRUST Co now owns 172 shares of the company's stock worth $33,000 after acquiring an additional 46 shares during the period. Next Level Wealth Planning LLC bought a new stake in shares of Moderna in the third quarter valued at about $34,000. Finally, Ramsey Quantitative Systems acquired a new position in shares of Moderna during the third quarter worth about $40,000. 75.33% of the stock is currently owned by institutional investors.

Moderna Company Profile

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company's commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.